MA-IBASIS
29.6.2021 08:02:06 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, announced it will partner with SIPPIO , the largest, secure, Azure-based provider of voice-calling services for Microsoft Teams, globally. The relationship enables both companies to address the fast-growing global demand for unified communications and collaboration services with Cloud Numbering and International Voice Termination.
The seismic shift to all cloud-based communication platforms is exemplified by Microsoft Teams’ 145 million daily active users. As recently reported by Synergy Group Research , “Microsoft has become the second-largest Unified Communications-as-a-Service (UCaaS) provider in the world.” As usage increases, so does the demand for exponentially growing voice calling services.
iBASIS and SIPPIO are responding to this demand with iBASIS’ expansion of Cloud Numbering and International Voice Termination combined with SIPPIO’s fully automated, end-to-end cloud solution platform, delivering top-grade communications and carrier services and leveraging automation to eliminate the cost, complexity, and time of building direct routing as a ‘one-off.’ This ensures both reliability and redundancy on a global scale with the highest levels of security, compliance, and data privacy.
iBASIS provides SIPPIO with enhanced coverage in various hard-to-reach destinations across the globe. Recent examples of iBASIS’ strengths in addressing demand from key geographies include iBASIS’ partnership with China Telecom Europe , which enabled CTE to achieve instant traction by leveraging iBASIS Carrier Voice for Teamwork™ to provide European multinationals with full calling capabilities to their collaboration platforms.
“SIPPIO is an innovative cloud solution player forging new capabilities and commercialization opportunities for fully automated, cloud-based direct routing as a service,” says Edwin van Ierland , Chief Commercial Officer and Chief Operating Officer at iBASIS. “This relationship showcases how iBASIS’ Carrier Cloud Communications portfolio , global reach, scale, and independence are critical to the global requirements for cloud communications.”
“This is a pivotal moment in which the demand to shift voice calling to the same world as online meetings is a major market driver,” adds Dawn-Marie Elder, COO, SIPPIO. “Partnering with iBASIS extends SIPPIO’s global footprint, reinforcing our ability to provide operators with the highest quality, tier-1 voice capabilities and fastest time to market to bring these solutions to their enterprise customers.”
iBASIS Carrier Voice for Teamwork is part of iBASIS’ larger Carrier Cloud Communications portfolio that includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS’ carrier-grade API marketplace includes a full CPaaS suite to meet the growing and urgent need for collaborative tools and applications – including solutions for iBASIS Carrier Voice for Teamwork™ , two-factor authentication, live support, and contact center services.
SIPPIO empowers channel partners and carriers with capabilities to capitalize on the demand for voice-enabled collaboration platforms like Microsoft Teams. By minimizing resource consumption from end to end, SIPPIO expands the universe of potential customers for partners, making it economically viable to pursue smaller companies as well as Fortune 500 enterprises.
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
About SIPPIO
Headquartered in Annapolis, MD, SIPPIO is the largest platform provider to enable voice in Microsoft Teams. As a Co-Sell Preferred partner, SIPPIO provides partners and carriers with a fully automated, Azure native, end-to-end solution. Available globally with toll-free and emergency services, SIPPIO does not require any code, build, or maintenance. SIPPIO activates full calling capabilities in minutes and scales with business needs to enhance communications and collaboration to unify the modern workplace experience. Visit www.sippio.io for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005768/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom